New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy

Abstract

PIN1 is considered as a therapeutic target for a wide variety of tumours. However, most of known inhibitors are devoid of cellular activity despite their good enzyme inhibitory profile. Hence, the lack of effective compounds for the clinic makes the identification of novel PIN1 inhibitors a hot topic in the medicinal chemistry field. In this work, we reported a virtual screening study for the identification of new promising PIN1 inhibitors. A receptor-based procedure was applied to screen different chemical databases of commercial compounds. Based on the whole workflow, two compounds were selected and biologically evaluated. Both ligands, compounds <b>VS1</b> and <b>VS2</b>, showed a good enzyme inhibitory activity and <b>VS2</b> also demonstrated a promising antitumoral activity in ovarian cancer cells. These results confirmed the reliability of our <i>in silico</i> protocol and provided a structurally novel ligand as a valuable starting point for the development of new PIN1 inhibitors.